Nov 15, 2023 9:30 AM EST
Nov 9, 2023 11:00 AM EST
Nov 8, 2023 3:20 PM EST
Nov 2, 2023 8:30 AM EDT
Oct 5, 2023
These slides contain the 60-week and 2-year (96-weeks) results from the Phase 3 PULSAR study of aflibercept 8 mg for nAMD. The presentation was given by Dr. Paolo Lanzetta at the 23rd EURETINA Congress on October 5, 2023.
Sep 11, 2023 9:20 AM EDT
Sep 6, 2023 8:45 AM EDT
Aug 3, 2023 8:30 AM EDT
Jul 29, 2023
These slides contain the 2-year (96 weeks) results from the Phase 2/3 PHOTON study of aflibercept 8 mg for DME. The presentation was given by Diana V. Do, MD at the American Society of Retina Specialists Annual Meeting on July 29, 2023.